Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Free Cash Flow (2021 - 2025)

Prime Medicine's Free Cash Flow history spans 5 years, with the latest figure at -$33.1 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 260.87% year-over-year to -$33.1 million; the TTM value through Dec 2025 reached -$162.7 million, down 31.17%, while the annual FY2025 figure was -$162.7 million, 31.17% down from the prior year.
  • Free Cash Flow reached -$33.1 million in Q4 2025 per PRME's latest filing, up from -$35.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $20.6 million in Q4 2024 to a low of -$68.5 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$35.5 million, with a median of -$35.7 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: surged 139.55% in 2024, then tumbled 260.87% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$10.2 million in 2021, then tumbled by 202.88% to -$30.8 million in 2022, then crashed by 69.01% to -$52.1 million in 2023, then surged by 139.55% to $20.6 million in 2024, then crashed by 260.87% to -$33.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Free Cash Flow are -$33.1 million (Q4 2025), -$35.3 million (Q3 2025), and -$43.0 million (Q2 2025).